Verastem Oncology Doses First Patient in TARGET-D 201 Trial
BOSTON, June 16, 2026 Verastem Oncology announced that the first patient has been dosed in the TARGET-D 201 Phase...
clinical trial
Advertisement
IDEAYA Launches Phase 1/2 Study of IDE892 in MTAP-Deleted Cancers
SOUTH SAN FRANCISCO, Calif., June 15, 2026 IDEAYA Biosciences has announced the initiation of a Phase 1/2 clinical combination...
TuHURA Files IND for TBS-2025 in AML and Blood Cancers
TAMPA, Fla., June 15, 2026 TuHURA Biosciences, Inc. has announced the filing of an Investigational New Drug (IND) application...
CytoDyn Doses First Patient in Phase 2a Alzheimer’s Trial of Leronlimab
VANCOUVER, Wash., June 11, 2026 CytoDyn Inc. announced that the first patient has been dosed in the Phase 2a...
HUTCHMED Reports Positive Phase III Sovleplenib Results in wAIHA
Hong Kong, Shanghai & Florham Park, N.J., June 12, 2026 HUTCHMED (China) Limited announced positive results from the Phase...
Advertisements
Immunome Doses First Patient in Phase 1 Trial of IM-1617
BOTHELL, Wash., June 11, 2026 Immunome, Inc. announced the first patient has been dosed in a Phase 1 first-in-human...
Heartseed Initiates World’s First Catheter-Based iPS Heart Therapy Study
TOKYO, Japan, June 2026 Heartseed Inc. announced the successful treatment of the first patient in its Phase I/II EMERALD...
Sanofi’s Tzield Gains FDA Approval in Stage 3 Type 1 Diabetes
PARIS, France, June 13, 2026 Sanofi has achieved a major breakthrough in diabetes care after the U.S. Food and...
AbbVie Reports 9-Year VENCLEXTA Data in First-Line CLL
NORTH CHICAGO, Ill., June 12, 2026 AbbVie announced new long-term clinical results from the Phase 3 CLL14 trial at...
Novo Nordisk Secures UK Approval for First Wegovy Weight-Loss Pill
BAGSVÆRD, Denmark, June 11, 2026 Novo Nordisk announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has...
Advertisement
